Original Article · Originalarbeit
Possible Relationship between Basal-Like Breast Carcinoma and AgeSchmitt Polidoro A.a · Mucha Dufloth R.b · Couto Vieira D.S.b · Zeferino L.C.c · Schmitt F.da Department of Pathology, University of Campinas (UNICAMP), Campinas, São Paulo, b Department of Pathology, Federal University of Santa Catarina, Florianópolis, Santa Catarina, c Department of Obstetrics and Gynecology, Faculty of Medical Sciences, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil, dMedical Faculty of Porto University and Institute of Pathology and Molecular Immunology, Porto University, Porto, Portugal
Rozany Mucha Dufloth Rodovia Amaro Antônio Vieira, 2463 Apto. 506 C Residencial Solar de Francavilla, Itacorubi 88034–102 Florianópolis, SC, Brazil Tel. +55 48 33319-473, Fax -542 rozany.ufsc@gmail.com |
|
Do you have an account?
Abstract
Introduction: Estrogen receptor expression is lower in breast carcinoma of women ≤45 years compared to women ≥65 years of age, which may imply a higher frequency of basal-like breast carcinomas in younger women. This study evaluated whether there is any difference in the frequency of basal-like phenotype and estrogen receptor (ER)–/HER2– invasive breast carcinomas between women of these 2 different age groups. Patients and Methods: A total of 151 women aged ≤45 years or ≥65 years with invasive breast carcinomas were evaluated using tissue microarray, and classified into the following phenotypes: luminal A (ER+/HER2–), luminal B (ER+/HER2+), HER2 overexpression (ER–/HER2+), and basal-like (ER–/HER2– and expressing at least 1 of the basal markers p63, CK5 and/or P-cadherin). Results: ER–/HER2– carcinomas were twice as frequent in women aged ≤45 years (p = 0.0247). However, when the basal-like phenotype was compared with all the other phenotypes grouped together, no statistically significant difference was found (p = 0.0854). Conclusions: ER–/HER2– carcinomas were more frequent in younger women compared to all the other phenotypes grouped together. An international consensus will be necessary to establish which markers should be used to define basal-like phenotype.
© 2009 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: June 15, 2009
Issue release date: June 2009
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 1661-3791 (Print)
eISSN: 1661-3805 (Online)
For additional information: https://www.karger.com/BRC
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID